PEB
29/01/2014 14:28
GENERAL
REL: 1428 HRS Pacific Edge Limited
GENERAL: PEB: Cxbladder boosting confidence in bladder cancer detection
January 29, 2014
Cxbladder Boosting Confidence in Bladder Cancer Detection in the US
New, urine based test offers patients greater peace of mind from accurate ,
reliable results.
HERSHEY, PA- Bladder cancer patients, survivors, and families faced with
life-long surveillance of the highly recurring disease are finding
reassurance in Cxbladder. This new, non-invasive, urine based bladder cancer
detection test developed by Pacific Edge Ltd measures the expression of five
genes that create a unique molecular signature for bladder cancer, alerting
doctors to possible tumors. More accurate1 than many other urine-based
cancer detection tests, Cxbladder can give patients and doctors added
confidence in their diagnoses.
Bladder cancer has a very high rate of recurrence and often progresses
quickly. Consequently bladder cancer patients live in a world of ongoing
monitoring and clinical intervention, much of it is invasive and expensive.
Cxbladder offers patients a non-invasive, accurate test for the detection of
bladder cancer. This test is available from Pacific Edge in several countries
around the world and is now available in the US from Pacific Edge's new,
dedicated CLIA laboratory and commercial headquarters in Hershey,
Pennsylvania.
"I have been using Cxbladder extensively since June 2011. Over that time
period, Cxbladder has proven to be the most accurate, non-invasive test for
monitoring patients with either hematuria or known bladder cancer." says Dr.
Joe DiTrolio, a Board Certified Urologist, Professor of Surgery, Section of
Urology/Department of Surgery Rutgers New Jersey Medical School.
Cxbladder is being utilized by clinicians to provide a number of clinical and
patient advantages. The test can be used on patients presenting with
hematuria to rule in or rule out the presence of bladder cancer; saving many
patients the inconvenience, invasiveness and cost of a full urological
workup.
Researchers at Pacific Edge found that messenger RNA (mRNA) levels of
specific biomarker genes are typically present at higher levels in urine
samples of patients that are positive for bladder cancer compared to urine
samples from patients who are negative for the disease.
The performance of the Cxbladder test was evaluated in a formal clinical
study and was been published in the Journal of Urology in 2012. The study
shows that Cxbladder outperformed all of the other clinical technologies that
were evaluated alongside it. In this study1Cxbladder correctly identified
100% of late stage tumors and 97% of high-grade tumors.
Just a small sample of urine is required for the test. Patient samples are
collected in an easy, simple to use urine sampling system, analyzed at
Pacific Edge Diagnostics' CLIA-certified and CAP-accredited laboratory in
Hershey, Pennsylvania, and the results are sent to the physician within seven
business days.
"The Cxbladder test is a wonderful new diagnostic tool in our evaluation
process for patients with new onset hematuria and for patients who are being
followed with known bladder cancer", says Dr. Guy Bernstein, a Board
Certified Urologist at Urology Health Specialists in Bryn Mawr, PA.
"Cxbladder is a quick, cost effective, non-invasive, accurate cancer
detection test that has significant advantages to both patients and
healthcare providers", says Jackie Walker, CEO of Pacific Edge Diagnostics
USA. "We are committed to fighting this disease, and early and accurate
detection is a key part of that."
More than seven million Americans will have some form of blood in their urine
(hematuria) resulting in more than one million undergoing evaluation this
year for bladder cancer. It is estimated that 1 in 42 Americans will develop
bladder cancer in their lifetime . The very high recurrence of this disease
following a positive diagnosis requires some patients to receive expensive
monitoring for the rest of their lives. Bladder cancer has the highest total
medical costs of any cancer per patient. Nearly $3 billion is spent to treat
bladder cancer each year in the US.
Contact:
Jackie Walker
1214 Research Blvd.
Suite 2000
Hummelston, PA 17036
www.cxbladder.com
Phone: (717) 220-7005
[email protected]
Recent news links:
1.
http://www.pacificedge.co.nz/news-and-media/news/pacific-edge-agreement-with-
national-providernetwork-fedmed-gives-40-million-americans-access-to-cxbladde
r/;http://www.pacificedge.co.nz/news-and-media/news/pacific-edge-signs-agreem
ent-with-americas-choice-provider-network-to-expand-access-to-cxbladder-in-th
e-us/
2.
http://www.pacificedgedx.com/news-and-media/news/first-commercial-sales-achie
ved-for-pacificedges-cxbladder-in-the-usa/
Patient education materials about Cxbladder are available at
www.cxbladder.com. Pacific Edge also offers a Patient Financial Assistance
Program to ensure access to this cutting edge test.
For more information about Cxbladder, contact Customer Service at Pacific
Edge Diagnostics USA Ltd. at 1-855-CXBLADR (1-855-292-5237) or visit the
website: www.cxbladder.com.
ABOUT PACIFIC EDGE LTD
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specializing in the discovery and commercialization of diagnostic and
prognostic technology for the early detection and monitoring of cancer.
Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterization and better management of gastric, bladder, colorectal
cancers and melanoma. The company has recently completed and released its
first product for the detection of bladder cancer, Cxbladder, and is actively
marketing the product to urologists in the US, New Zealand, Australia, and
soon to be in Spain.
www.pacificedge.co.nz
ABOUT PACIFIC EDGE DIAGNOSTICS USA LTD
Pacific Edge Diagnostics USA LTD is a subsidiary of Pacific Edge Limited, a
cancer diagnostics company specializing in the discovery and
commercialization of diagnostic and prognostic technology for the early
detection and monitoring of cancer. Pacific Edge provides centralized
diagnostic services through its facilities in the US and New Zealand.
Pacific Edge products are based on proprietary genetic databases used to
identify diagnostic biomarkers for cancers.
End CA:00246470 For:PEB Type:GENERAL Time:2014-01-29 14:28:40
